[HTML][HTML] The initial interplay between HIV and mucosal innate immunity

V Caputo, M Libera, S Sisti, B Giuliani… - Frontiers in …, 2023 - frontiersin.org
Human Immunodeficiency Virus (HIV) is still one of the major global health issues, and
despite significant efforts that have been put into studying the pathogenesis of HIV infection …

Innate antiviral immunity: how prior exposures can guide future responses

JA Tomalka, MS Suthar, MS Diamond, RP Sekaly - Trends in Immunology, 2022 - cell.com
Innate immunity is an intrinsic baseline defense in cells, with its earliest origins in bacteria,
and with key roles in defense against pathogens and in the activation of B and T cell …

[HTML][HTML] Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates

MD Fahlberg, RV Blair, LA Doyle-Meyers… - Nature …, 2020 - nature.com
Understanding SARS-CoV-2 associated immune pathology is crucial to develop pan-
effective vaccines and treatments. Here we investigate the immune events from the acute …

[HTML][HTML] Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells

WA van der Heijden, L Van de Wijer, F Keramati… - JCI insight, 2021 - ncbi.nlm.nih.gov
Chronic inflammation and immune dysfunction play a key role in the development of non-
AIDS–related comorbidities. The aim of our study was to characterize the functional …

[HTML][HTML] The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination

JA Tomalka, AN Pelletier, S Fourati, MB Latif… - Nature …, 2021 - nature.com
Abstract Development of effective human immunodeficiency virus 1 (HIV-1) vaccines
requires synergy between innate and adaptive immune cells. Here we show that induction of …

Analysis of the HIV Vaccine Trials Network 702 phase 2b–3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk

Z Moodie, O Dintwe, S Sawant, D Grove… - The Journal of …, 2022 - academic.oup.com
Abstract Background The ALVAC/gp120+ MF59 vaccines in the HIV Vaccine Trials Network
(HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) …

[HTML][HTML] HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC

M Bissa, S Kim, V Galli, S Fourati, S Sarkis… - Nature …, 2023 - nature.com
The development of an effective vaccine to protect against HIV acquisition will be greatly
bolstered by in-depth understanding of the innate and adaptive responses to vaccination …

[HTML][HTML] Strategies for developing and optimizing cancer vaccines

HM Maeng, JA Berzofsky - F1000Research, 2019 - ncbi.nlm.nih.gov
With the spotlight on cancer immunotherapy and the expanding use of immune checkpoint
inhibitors, strategies to improve the response rate and duration of current cancer …

[HTML][HTML] HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge

AT Jones, X Shen, KL Walter, CC LaBranche… - Nature …, 2019 - nature.com
The oral mucosa is an attractive site for mucosal vaccination, however the thick squamous
epithelium limits antigen uptake. Here we utilize a modified needle-free injector to deliver …

[HTML][HTML] Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques

C Petitdemange, SP Kasturi, PA Kozlowski, R Nabi… - JCI insight, 2019 - ncbi.nlm.nih.gov
Antibodies and cytotoxic T cells represent 2 arms of host defense against pathogens. We
hypothesized that vaccines that induce both high-magnitude CD8+ T cell responses and …